We are a team of scientists, clinicians, and engineers on a mission to disrupt the standard of care for chronic and infectious lung disease. Our proprietary resMIT platform delivers safe, targeted bacteria directly to the lungs to address fibroblast dysfunction in Idiopathic Pulmonary Fibrosis (IPF) and neutrophilic inflammation indications (NCFBE, COPD).